Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/8/2020
SIETES contiene 93083 citas

 
 
 1 a 20 de 86 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Koblan KS, Kent J, Hopkins SC, Krystal JH, Cheng H, Goldman R, Loebel A. A non–D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med 2020;382:1497-506. [Ref.ID 103592]
2. Cita con resumen
Janiri D, Doucet GE, Pompili M, Sani G, Luna B, Brent DA, Frangou S. Risk and protective factors for childhood suicidality: a US population-based study. The Lancet Psychiatry 2020:12 de marzo. [Ref.ID 103552]
3. Cita con resumen
Dalsgaard S, Thorsteinsson E, Trabjerg BB, Schullehner J, Plana-Ripoll O, Brikell I, Wimberley T, Thygesen M, Bang Madsen K, Timmerman A, Schendel D, McGrath JJ, Mortensen PB, Pedersen CB. Incidence rates and cumulative incidences of the full spectrum of diagnosed mental disorders in childhood and adolescence. JAMA Psychiatry 2019:20 de noviembre. [Ref.ID 103222]
4. Cita con resumen
Ji Y, Azuine RE, Zhang Y, Hou W, Hong X, Wang G, Riley A, Pearson C, Zuckerman B, Wang X. Association of cord plasma biomarkers of in utero acetaminophen exposure with risk of attention-deficit/hyperactivity disorder and autism spectrum disorder in childhood. JAMA Psychiatry 2019:30 de octubre. [Ref.ID 103208]
5. Cita con resumen
6.Enlace a cita original Cita con resumen
Waxmonsky JG, Pelham W 3rd, Campa A, Waschbusch DA, Li T, Marshall R, Babocsai L, Humphery H, Gnagy E, Swanson J, Hanc T, Fallahazad N, Pelham WE 4th. A randomized controlled trial of interventions for growth suppression in children with attention-deficit/hyperactivity disorder treated with central nervous system stimulants. J Am Acad Child Adolesc Psychiatry 2019:29 de agosto. [Ref.ID 103191]
7.Enlace a cita original Cita con resumen
Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 2019;176:1 de junio. [Ref.ID 103133]
8.Enlace a cita originalTiene citas relacionadas Cita con resumen
Cortese S. Psychosis during attention deficit–hyperactivity disorder treatment with stimulants. N Engl J Med 2019;380:21 de marzo. [Ref.ID 103068]
9.Enlace a cita originalTiene citas relacionadas Cita con resumen
Moran LV, Ongur D, Hsu J, Castro VM, Perlis RH, Schneeweiss S. Psychosis with methylphenidate or amphetamine in patients with ADHD. N Engl J Med 2019;380:21 de marzo. [Ref.ID 103067]
10.Enlace a cita original Cita con resumen
Gobbi G, Atkin T, Zytnski T, Zytynski T, Wang S, Askari S, Boruff J, Ware M, Marmorstein N, Cipriani A, Dendukuri N, Mayo N. Association of cannabis use in adolescence and risk of depression, anxiety, and suicidality in young adulthood. A systematic review and meta-analysis. JAMA Psychiatry 2019;76:13 de febrero. [Ref.ID 103030]
11.Enlace a cita original Cita con resumen
Valles-Colomer M, Falongy G, Darzi Y, Tigchelaar EF, Wang J, Tito RY, Schiweck C, Kurilshikov A, Joossens M, Wijmenga C, Claes S, Van Oudenhove L, Zhernakova A, Vieira-Silva S, Raes J. The neuroactive potential of the human gut microbiota in quality of life and depression. Nat Microbiol 2019:4 de febrero. [Ref.ID 103027]
12.Enlace a cita original Cita con resumen
Josephson CB, Engbers JDT, Jette N, Patten SB, Sinqh S, Sajobi TT, Marshall D, Agha-Khani Y, Federico P, Mackie A, Macrodimitris S, McLane B, Pillay N, Sharma R, Wiebe S. Prediction tools for psychiatric adverse effects after levetiracetam prescription. JAMA Neurology 2019:enero. [Ref.ID 103020]
13.Enlace a cita original Cita con resumen
Christensen J, Pedersen LH, Sun Y, Dreier JW, Brikell I, Dalsqaard S. Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit/hyperactivity disorder in offspring. JAMA Network Open 2019;2:4 de enero. [Ref.ID 103010]
14.Enlace a cita originalTiene citas relacionadas Cita con resumen
Ray WA, Stein CM, Murray KT, Fuchs DC, Patrick SW, Daugherty J, Hall K, Cooper WO. Association of antipsychotic treatment with risk of unexpected death among children and youths. JAMA Psychiatry 2018:12 de diciembre. [Ref.ID 102895]
15. Cita con resumen
Healy D. The Goetzsche affair. Dr. David Healy (blog) 2018:5 de noviembre. [Ref.ID 102892]
16. Cita con resumen
Thielking M. Life expectancy down as suicides, overdoses rise. STAT Morning Rounds 2018:2. [Ref.ID 102856]
17.Enlace a cita original Cita con resumen
Vedal TSJ, Steen NE, Birkeland KI, Dieset I, Reponen EJ, Laskemoen JF, Rodevand L, Melle I, Andreassen OA, Molden E, Jönsson EG. Free thyroxine and thyroid-stimulating hormone in severe mental disorders: A naturalistic study with focus on antipsychotic medication. J Psychiatr Res 2018:25 de septiembre. [Ref.ID 102832]
18.Enlace a cita original Cita con resumen
Cortese A, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, Atkinson LZ, Tessari L, Banaschewski T, Coghill D, Hollis C, Simonoff E, Zuddas A, Barbui C, Purgato M, Steinhausen HC, Shokraneh F, Xia J, Cipriani A. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018:7 de agosto. [Ref.ID 102788]
19. Cita con resumen
Anónimo. Valproato (Depakine / Depakine Crono): programa de prevención de embarazos. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2018:24 de julio. [Ref.ID 102721]
20.Enlace a cita originalTiene citas relacionadas
Kerr MP. Guidance is needed on valproate in pregnancy for those without capacity. BMJ 2018;361:29 de mayo. [Ref.ID 102684]
Seleccionar todas
 
 1 a 20 de 86 siguiente >>